Wikidata

(Q105788772)

English

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

clinical trial

In more languages

Statements

short name
DB-06 (English)
0 references
title
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (English)
0 references
sponsor
AstraZeneca
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Canada
0 references
Denmark
0 references
France
0 references
Germany
0 references
Hungary
0 references
India
0 references
Israel
0 references
Italy
0 references
Mexico
0 references
Netherlands
0 references
Poland
0 references
Saudi Arabia
0 references
Spain
0 references
Sweden
0 references
Taiwan
0 references
start time
24 July 2020
0 references
end time
16 December 2022
0 references
number of participants
850
0 references
research intervention
paclitaxel
0 references
capecitabine
0 references
trastuzumab
0 references
minimum age
18 year
0 references
maximum age
105 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q105788772&oldid=2148629213"